What is Humira?

Adalimumab, trade names Humira ("human monoclonal antibody in rheumatoid arthritis") and Exemptia are TNF inhibiting anti-inflammatory drug manufactured by AbbVie and Zydus Cadila respectively.

Adalimumab binds to tumor necrosis factor-alpha (TNFα). TNFα normally binds to TNFα receptors, which leads to the inflammatory response of autoimmune diseases. By binding to TNFα, adalimumab reduces this inflammatory response. Adalimumab has been approved in the United States for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.

In rheumatoid arthritis, adalimumab has a response rate similar to methotrexate, and in combination nearly doubles the response rate of methotrexate alone.

Because TNFα is part of the immune system that protects the body from infection, treatment with adalimumab may increase the risk of infections.

It is marketed in 0.8 mL vials, preloaded 0.8 mL syringes and also in preloaded pen devices (called Humira Pen), injected subcutaneously, typically by the patient at home. It cannot be administered orally because the digestive system would destroy the drug.

Adalimumab was the first fully human monoclonal antibody drug approved by the FDA. It was derived from phage display, and was discovered through a collaboration between BASF Bioresearch Corporation (Worcester, Massachusetts, a unit of BASF) and Cambridge Antibody Technology as D2E7, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. On January 1, 2013 Abbott split into two companies, one retaining the Abbott name and the other named AbbVie. Humira is now owned by AbbVie.

Humira costs approximately $3,100 per month, like the TNF-alpha inhibitor etanercept (Enbrel).

In 2012, Humira had $4.3 billion of sales in the US, and $9.3 billion worldwide.

In December 2014, Cadila Healthcare Ltd., launched in India the first Adalimumab biosimilar, under the name '''Exemptia''', at a price of $200 a vial. Humira's U.S. patent will expire in 2016.

Questions and answers on "Humira"

Hello! I can't seem to get any good info on the increase of liver enzymes with the use of humira. My husband is an alcoholic, and he takes humira....

doctor1 MD

CDT test is specific for alcohol abuse,a value of 1.2 needs other supportive tests such as GGT need to be done.Humira also tends to cause liver...

Read Full Thread   Ask a Doctor Now

My daughter has Crohn s and is currently on Humira, one shot every week. Every month either before or after her mentrual cycle she has really bad...

doctor1 MD

Hello ma'am and welcome.

The cause could be either hormonal or what you described as 'something healing in the ileum'. Wasthis an ulcer? I would...

Read Full Thread   Ask a Doctor Now

Started Humira three months ago, got severe psorisis on my hands. I have poriatic arthritis , so have had before, but this is worse. My skin keeps...

doctor1 MD

Hi ,
Thanks for the details.
Humira is a biological drug for psoriasis.It will not cause psoriasis or itching.
You can continue Humira. Also...

Read Full Thread   Ask a Doctor Now

Recent questions on Humira

Ask Question
Doctor Image

Hi, I am Dr. Andrew Rynne (Family Physician). I will be guiding you through the process. Please write your question below.

Related Drugs/Medications
Related Lab Tests
Related Procedures